TY - JOUR
T1 - Effects of demethylating agent 5-aza-2′-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines
AU - Murakami, Jun
AU - Asaumi, Jun Ichi
AU - Maki, Yuu
AU - Tsujigiwa, Hidetsugu
AU - Kuroda, Masahiro
AU - Nagai, Noriyuki
AU - Yanagi, Yoshinobu
AU - Inoue, Tetsuyoshi
AU - Kawasaki, Shoji
AU - Tanaka, Noriaki
AU - Matsubara, Nagahide
AU - Kishi, Kanji
N1 - Funding Information:
This work was supported by a Grant-in-Aid (14571198, 14771134, 15592112) for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.
PY - 2004/7
Y1 - 2004/7
N2 - Maspin, which belongs to the serine protease inhibitor (serpin) superfamily, has been proposed as a potent tumor suppressor that inhibits cell motility, invasion, angiogenesis, and metastasis. In the present study, we examined the effects of 5-aza-2′-deoxycytidine (5-aza-dC), a demethylating agent, and FR901228, a histone deacetylase (HDAC) inhibitor, on maspin expression in oral cancer cell lines. The expression levels of maspin mRNA were divided into two groups, which was the maspin low-expressed and high-expressed cell lines in the 12 oral cancer cell lines. The maspin promoter contained only a few methylated CpG sites in the maspin low-expressed cell lines. Moreover, the methylation status was not altered after 5-aza-dC treatment. However, the transcription of the maspin gene was clearly increased following 5-aza-dC treatment in a number of oral cancer cell lines. These results imply that an action of 5-aza-dC is separate from induction of promoter demethylation. Treatment with FR901228 resulted in a time-dependent stimulation of the re-expression of maspin mRNA as early as 4 h after treatment in the maspin downregulated cells. The re-expression of the maspin gene may contribute to the recuperation of biological functions linked to FR901228 such as an inhibitory effect on tumor angiogenesis and cell invasion. These results indicate that maspin and its target genes may be excellent leads for future studies on the potential benefits of FR901228, a HDAC inhibitor, in cancer therapy.
AB - Maspin, which belongs to the serine protease inhibitor (serpin) superfamily, has been proposed as a potent tumor suppressor that inhibits cell motility, invasion, angiogenesis, and metastasis. In the present study, we examined the effects of 5-aza-2′-deoxycytidine (5-aza-dC), a demethylating agent, and FR901228, a histone deacetylase (HDAC) inhibitor, on maspin expression in oral cancer cell lines. The expression levels of maspin mRNA were divided into two groups, which was the maspin low-expressed and high-expressed cell lines in the 12 oral cancer cell lines. The maspin promoter contained only a few methylated CpG sites in the maspin low-expressed cell lines. Moreover, the methylation status was not altered after 5-aza-dC treatment. However, the transcription of the maspin gene was clearly increased following 5-aza-dC treatment in a number of oral cancer cell lines. These results imply that an action of 5-aza-dC is separate from induction of promoter demethylation. Treatment with FR901228 resulted in a time-dependent stimulation of the re-expression of maspin mRNA as early as 4 h after treatment in the maspin downregulated cells. The re-expression of the maspin gene may contribute to the recuperation of biological functions linked to FR901228 such as an inhibitory effect on tumor angiogenesis and cell invasion. These results indicate that maspin and its target genes may be excellent leads for future studies on the potential benefits of FR901228, a HDAC inhibitor, in cancer therapy.
KW - 5-Aza-2-deoxycytidine
KW - FR901228
KW - Maspin
KW - Methylation
UR - http://www.scopus.com/inward/record.url?scp=11144356238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144356238&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2003.12.008
DO - 10.1016/j.oraloncology.2003.12.008
M3 - Article
C2 - 15063388
AN - SCOPUS:11144356238
SN - 1368-8375
VL - 40
SP - 597
EP - 603
JO - Oral Oncology
JF - Oral Oncology
IS - 6
ER -